Epirubicin hydrochloride (CAS 56390-09-1) is a potent anthracycline antineoplastic agent and the 4’-epimer of doxorubicin. It is widely used, often as epirubicin, in combination chemotherapy regimens for breast cancer and other solid tumours. As with other anthracyclines, epirubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis in rapidly dividing cells.
Epirubicin HCl 56390-09-1 from TCS GROUP is offered as a high-quality Active Pharmaceutical Ingredient (API) for injectable formulations. Compared with doxorubicin, epirubicin is often described as having a somewhat different toxicity profile, allowing higher cumulative doses in certain regimens while maintaining strong antitumour activity. Treatment, however, must still carefully monitor for cardiotoxicity, myelosuppression and mucosal toxicity, which are characteristic of this drug class.
Within the TCS INDUSTRIES LIMITED
Active Pharmaceutical Ingredient
portfolio, epirubicin HCl forms part of a coherent oncology range that also includes:
- Doxorubicin HCl 25316-40-9 – the reference anthracycline widely used in numerous solid and hematologic malignancies.
- Carmustine 154-93-8 – a nitrosourea alkylating agent used in brain tumours and multi-agent lymphoma regimens.
Manufacturing epirubicin HCl requires high-containment facilities, strict control of impurities and robust worker protection due to its potent cytotoxicity. Typical presentations are lyophilised or solution injectables, with careful attention to pH, solvent systems, light protection and reconstitution stability.
From a development perspective, having access to both Epirubicin HCl and Doxorubicin HCl from the same supplier allows oncology companies to streamline audits, stability comparisons and regulatory submissions. TCS GROUP supports customers with technical data, stability information and documentation aligned with global oncology standards.